Rubicon Research Ltd (RUBICON) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 544578 | NSE: RUBICON | Miscellaneous | Small Cap

Rubicon Research Share Price

662.10 -16.35 -2.41%
as on 02-Jan'26 16:59

DeciZen - make an informed investing decision on Rubicon Research

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Rubicon Research stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
66.72
Market Cap:
11,177.5 Cr.
52-wk low:
571
52-wk high:
888

Is Rubicon Research Ltd an attractive stock to invest in?

1. Is Rubicon Research Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Rubicon Research Ltd is a average quality company.

2. Is Rubicon Research Ltd undervalued or overvalued?

The key valuation ratios of Rubicon Research Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Rubicon Research Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Rubicon Research Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Rubicon Research:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Rubicon Research Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 7.4%3%1.6%14.4%28.2%21.2%4.7%5.5%7.9%26.7%-
Value Creation
Index
-0.5-0.8-0.90.11.10.6-0.7-0.6-0.40.9-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 39.248.965.21542633314004076311,0741,074
Sales YoY Gr.-24.8%33.4%136%71%26%20.7%1.9%54.7%70.3%-
Adj EPS 0.20.10.11.33.33.21.1-0.30.910.510.2
YoY Gr.--40%-22.2%1757.1%154.6%-3.9%-65.4%-123.6%NA1105.8%-
BVPS (₹) 4.812.912.714.322.826.327.428.229.741.676.2
Adj Net
Profit
0.91.20.918.450.448.316.8-413.2162168
Cash Flow from Ops. 7.6-4.3-15.4-10.79.346.9-37.1-7983.229.7-
Debt/CF from Ops. 3.8-6.4-1.9-4.73.32-4.6-44.813.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 44.5%32.5%39%70.3%
Adj EPS 60.3%26%112.1%1105.8%
BVPS27.2%12.8%15%40%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
1.91.10.59.718.112.64-0.92.928.317.3
Op. Profit
Mgn %
25.117.88.223.234.133.61010.211.625.225
Net Profit
Mgn %
2.32.51.41219.214.64.2-12.115.115.6
Debt to
Equity
0.60.20.20.30.10.20.40.70.90.60.2
Working Cap
Days
342330365272256274324457371288143
Cash Conv.
Cycle
13115117812213916417626419413457

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 17.30%

Sales growth is growing at healthy rate in last 3 years 38.98%

Net Profit is growing at healthy rate in last 3 years 112.06%

Debt to equity has declined versus last 3 years average to 0.61

Sales growth is good in last 4 quarters at 16.00%

No data to display

Latest Financials - Rubicon Research Ltd.

Standalone Consolidated
TTM EPS (₹) 10.2 8.2
TTM Sales (₹ Cr.) 1,074 1,284
BVPS (₹.) 76.2 69.6
Reserves (₹ Cr.) 1,240 1,130
P/BV 8.90 9.75
PE 66.72 83.19
From the Market
52 Week Low / High (₹) 571.00 / 887.95
All Time Low / High (₹) 571.00 / 887.95
Market Cap (₹ Cr.) 11,177
Equity (₹ Cr.) 16.5
Face Value (₹) 1
Industry PE 75.1

Management X-Ray of Rubicon Research:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Rubicon Research - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Rubicon Research

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales3949651542633314004076311,074
Operating Expenses 294060119173220360366557804
Manufacturing Costs334726631109379109
Material Costs5914354555103125214308
Employee Cost 121422283441597485128
Other Costs 1014204968618874179259
Operating Profit 10953590111404173270
Operating Profit Margin (%) 25.1%17.7%8.2%22.8%34.1%33.6%10.0%10.2%11.6%25.1%
Other Income 0146181117282620
Interest 3323699193134
Depreciation 5568182832333532
Exceptional Items 0000000000
Profit Before Tax 311318485171834223
Tax 20092532061056
Profit After Tax 111225953171324168
PAT Margin (%) 2.3%2.5%1.5%14.2%22.5%16.0%4.2%3.1%3.9%15.6%
Adjusted EPS (₹)0.20.10.11.63.93.51.10.81.610.9
Dividend Payout Ratio (%)0%0%0%0%2%1%5%2%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 48181179201347399416429452642
Share Capital 2155555551515
Reserves 27177174196342394411424437626
Minority Interest0000000000
Debt242326422482155293357355
Long Term Debt912122843863979364
Short Term Debt15111414194391196264290
Trade Payables4410192232587498184
Others Liabilities 1514153848574972109159
Total Liabilities 922232303004425706788681,0161,339

Fixed Assets

Gross Block657582111211265299334410461
Accumulated Depreciation283438436088119152178202
Net Fixed Assets 37414468151177181183232259
CWIP 1516255724325106
Investments 01157818353219263436
Inventories27141938575899181258
Trade Receivables19243784140154234350252501
Cash Equivalents 1229337944464837
Others Assets 181830454267142139259241
Total Assets 922232303004425706788681,0161,339

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 8-4-15-11947-37-798330
PBT 311318485171834223
Adjustment 651016202625405268
Changes in Working Capital 1-10-26-57-68-31-71-13613-235
Tax Paid -2-1-0-0-27-33-8-0-16-27
Cash Flow From Investing Activity -8-122171-85-32-86-34-130-10
Capex -8-7-23-64000-37-56-70
Net Investments 00-3-4-14300-11-4
Others -0-1144270-72-35-863-6364
Cash Flow From Financing Activity -0127-31676526512446-34
Net Proceeds from Shares 014700000008
Net Proceeds from Borrowing 000002804410-30
Interest Paid -3-3-2-2-6-10-18-28-33
Dividend Paid 000000-1-0-0-0
Others 2-17-119822566986421
Net Cash Flow -11-16-067-5811-1-14

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)3.161.150.5311.4821.5514.194.093.015.5330.64
ROCE (%)7.443.021.6214.4328.2121.214.715.457.9126.65
Asset Turnover Ratio0.450.310.290.580.710.660.640.530.670.91
PAT to CFO Conversion(x)8-4-15-0.50.150.89-2.18-6.083.460.18
Working Capital Days
Receivable Days166162172144156162177262174128
Inventory Days14356040405252708175
Payable Days248168190154168180160194147167

Rubicon Research Ltd Stock News

Rubicon Research Ltd FAQs

The current trading price of Rubicon Research on 02-Jan-2026 16:59 is ₹662.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-2026 the market cap of Rubicon Research stood at ₹11,177.5.
The latest P/E ratio of Rubicon Research as of 01-Jan-2026 is 66.72.
The latest P/B ratio of Rubicon Research as of 01-Jan-2026 is 8.90.
The 52-week high of Rubicon Research is ₹888.0 and the 52-week low is ₹571.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Rubicon Research is ₹1,074 ( Cr.) .

About Rubicon Research Ltd

Rubicon Research was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name ‘Rubicon Consultants Private Limited’, pursuant to a certificate of incorporation issued by the RoC.

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and the company), it is the only Indian pharmaceutical player with a complete focus on regulated markets.

The company’s multi-disciplinary, data-driven, and return on investment (ROI) centric product selection framework is geared towards identifying sustainable opportunities for new product development. It identifies and pursues such opportunities in a manner that provides it a competitive advantage by leveraging its development, manufacturing, and commercialization capabilities to create and grow its share of the market.

Business area of the company

Rubicon Research, incorporated in 1999, is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. Further, the company has robust sales and distribution capabilities in the US.

Products of the company

  • Metoprolol Tartrate
  • Cyclobenzaprine Hydrochloride
  • Carbidopa-Levodopa
  • Diclofenac Potassium
  • Baclofen
  • Rabeprazole Sodium
  • Lidocaine Hydrochloride
  • Tramadol Hydrochloride

History and milestones

  • 2007: Received investment from Kotak India Venture Fund - I, Kotak India Venture Limited and Kotak Employees Investment Trust.
  • 2011: Commencement of manufacturing of certain special drugs in Ambernath Manufacturing Facility.
  • 2011: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility for tablet manufacturing and secondary packaging by Medicines and Healthcare Products Regulatory Agency, United Kingdom.
  • 2013: Receipt of GMP clearance approval for Ambernath Manufacturing Facility from Department of Health and Ageing Therapeutic Goods Administration, Australian Government.
  • 2014: Receipt of approval for its product i.e., ‘metoprolol tartrate tablets’ from the Food & Drug Administration, United State of America.
  • 2016: Acquisition of majority stake by ECP III Pte Ltd.
  • 2017: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility from the Ministerio De Sandidad, Servicios Sociales E Igualdad, Spain.
  • 2019: Acquisition of majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd.
  • 2019: Acquisition of Impopharma Canada Limited by Rubicon Research Canada Limited
  • 2021: Acquired the business of Meditab Specialities Limited on a slump sale basis.
  • 2022: Set up own sales and marketing front end in US via its Material Subsidiary.
  • 2023: Receipt of certificate of GMP compliance for Satara Manufacturing Facility of non-sterile liquid drug manufacturer and pre-approval coverage provided for non-sterile liquid product by US FDA.
  • 2024: Acquisition of Validus Pharmaceuticals LLC.
  • 2024: ANDA pre-approval drug inspection of nasal spray block at Ambernath Manufacturing Facility by USFDA.
  • 2024: Receipt of supplement approval for Thane R&D Facility as a testing site of drug substance - lead test from USFDA.
  • 2024: Received USFDA establishment inspection report for Ambernath Manufacturing Facility.
  • 2024: Commencement of manufacturing of nasal products at Ambernath Manufacturing Facility.
  • 2025: Received new drug application approval from USFDA for Lopressor (Metoprolol Tartrate) oral solution.
  • 2025: Received USFDA establishment inspection report for Thane R&D Facility.
  • 2025: Acquisition of Pithampur Manufacturing Facility from Alkem Laboratories Limited.
  • 2025: Acquisition of AIM RX 3PL LLC.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×